JANX - Janux Therapeutics, Inc. News

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks C

Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analy

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy r

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should K

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the s

Here's Why You Should Add JANX Stock to Your Portfolio Now

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates,

Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight

Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks C

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While

seekingalpha.com

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runw

Jones Trading Maintains Buy on Janux Therapeutics, Lowers Price Target to $28

Jones Trading analyst Boris Peaker maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowe

Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move

Janux Therapeutics halts JANX008 after Phase 1a review, shifting focus to higher-priority programs d

Janux Therapeutics Discontinues JANX008 Cancer Program To Prioritize Higher-Potential Pipeline Oppor

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biop

Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14

Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Unde

Janux Therapeutics Doses First Participant In Phase 1 Clinical Study Of JANX014 To Treat Metastatic

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15

UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, sign

Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Brist

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaborati

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

defenseworld.net

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Anal

Shares of Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) have been assigned an average ra

Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $100

Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overwei

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $68

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t

Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analy

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highligh

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JAN

247wallst.com

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with cons

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move Th

The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in J

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company dev

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwid

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Janux Therapeutics Announces Collaboration And Exclusive Worldwide License Agreement With Bristol My

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company

Clear Street Downgrades Janux Therapeutics to Hold, Lowers Price Target to $12

Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold

Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $30

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight

Janux Therapeutics Provides Phase 1 Update on EGFR-Targeted JANX008; The Program Has Initiated Expan

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin

Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29

Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lo

Gold Down Over 1%; Signet Shares Fall After Q3 Results

Stifel Maintains Buy on Janux Therapeutics, Lowers Price Target to $38

Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers th

12 Health Care Stocks Moving In Tuesday's Intraday Session

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

JANX stock hit 52-week low after releasing Phase 1 data for JANX007 in mCRPC. Encouraging efficacy a

Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings

Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday